
Trevena TRVN
Quartalsbericht 2024-Q3
hinzugefügt 07.11.2024
Trevena Langfristiger Schuldenstrom 2011-2026 | TRVN
Langfristiger Schuldenstrom Jährlich Trevena
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 M | 890 K | 788 K | 696 K | 611 K | 12.6 M | 12.4 M | 5.04 M | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 12.6 M | 611 K | 4.25 M |
Langfristiger Schuldenstrom anderer Aktien in der Pharmaeinzelhändler
| Name | Langfristiger Schuldenstrom | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Applied Genetic Technologies Corporation
AGTC
|
1.27 M | - | - | $ 26.5 M | ||
|
MorphoSys AG
MOR
|
3.63 M | - | 2.43 % | $ 254 M | ||
|
Allakos
ALLK
|
3.25 M | - | - | $ 28.6 M | ||
|
Advaxis
ADXS
|
166 K | - | -9.65 % | $ 45.9 M | ||
|
Akouos
AKUS
|
671 K | - | 0.23 % | $ 488 M | ||
|
AlloVir
ALVR
|
316 K | - | 4.14 % | $ 49.1 M | ||
|
Compugen Ltd.
CGEN
|
768 K | $ 2.56 | -6.41 % | $ 239 M | ||
|
I-Mab
IMAB
|
8.06 M | - | - | $ 866 M | ||
|
Aeglea BioTherapeutics
AGLE
|
625 K | - | - | $ 1.01 B | ||
|
Ampio Pharmaceuticals
AMPE
|
274 K | - | -11.43 % | $ 502 K | ||
|
Aptorum Group Limited
APM
|
433 K | $ 0.89 | 1.48 % | $ 6.54 M | ||
|
ACADIA Pharmaceuticals
ACAD
|
9.96 M | $ 22.24 | -1.9 % | $ 3.69 B | ||
|
Evogene Ltd.
EVGN
|
716 K | $ 0.79 | -0.65 % | $ 27.9 M | ||
|
Fennec Pharmaceuticals
FENC
|
2 K | $ 6.15 | -8.21 % | $ 176 M | ||
|
Applied Molecular Transport
AMTI
|
4.64 M | - | - | $ 10.1 M | ||
|
AIkido Pharma
AIKI
|
554 K | - | 1.93 % | $ 17.4 M | ||
|
Galapagos NV
GLPG
|
1.73 M | $ 27.84 | -2.04 % | $ 2.69 B | ||
|
Applied Therapeutics
APLT
|
429 K | - | - | $ 8.42 M | ||
|
Aptinyx
APTX
|
337 K | - | -39.0 % | $ 4.57 M | ||
|
ImmuCell Corporation
ICCC
|
85.5 K | $ 8.42 | 0.88 % | $ 76 M | ||
|
Aeterna Zentaris
AEZS
|
215 K | - | 5.93 % | $ 314 M | ||
|
Innoviva
INVA
|
418 K | $ 23.07 | -2.62 % | $ 1.55 B | ||
|
Ayala Pharmaceuticals
AYLA
|
419 K | - | - | $ 7.46 M | ||
|
AgeX Therapeutics
AGE
|
181 K | - | -10.17 % | $ 12.2 K | ||
|
Aravive
ARAV
|
2.2 M | - | -13.39 % | $ 1.45 M | ||
|
Aridis Pharmaceuticals
ARDS
|
538 K | - | 17.91 % | $ 11.1 M | ||
|
Atreca
BCEL
|
3.54 M | - | -11.76 % | $ 5.79 M | ||
|
BioNTech SE
BNTX
|
45 M | $ 100.23 | -1.8 % | $ 27.2 B | ||
|
Brainstorm Cell Therapeutics
BCLI
|
208 K | - | -2.5 % | $ 5.88 M | ||
|
Jaguar Health
JAGX
|
192 K | $ 0.23 | -5.81 % | $ 536 K | ||
|
Aquestive Therapeutics
AQST
|
631 K | $ 4.04 | -1.34 % | $ 432 M | ||
|
Arcutis Biotherapeutics
ARQT
|
294 K | $ 22.36 | -3.99 % | $ 2.84 B | ||
|
KalVista Pharmaceuticals
KALV
|
1.62 M | $ 26.71 | 38.8 % | $ 1.44 B | ||
|
Kamada Ltd.
KMDA
|
2.12 M | $ 8.15 | - | $ 260 M | ||
|
Autolus Therapeutics plc
AUTL
|
4.56 M | $ 1.42 | -4.39 % | $ 378 M | ||
|
Aptose Biosciences
APTO
|
193 K | - | -45.71 % | $ 1.2 M | ||
|
AstraZeneca PLC
AZN
|
382 M | - | - | $ 96.9 B | ||
|
AVROBIO
AVRO
|
878 K | - | 1083.1 % | $ 745 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
43 K | $ 2.95 | 1.2 % | $ 4.86 M | ||
|
BeiGene, Ltd.
BGNE
|
20.7 M | - | 0.49 % | $ 251 B |